



# THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Establishing a Core Outcome Measure for Graft Health

**Citation for published version:**

Tong, A, Sautenet, B, Poggio, ED, Lentine, KL, Oberbauer, R, Mannon, R, Murphy, B, Padilla, B, Chow, KM, Marson, L, Chadban, S, Craig, JC, Ju, A, Manera, KE, Hanson, CS, Josephson, MA & Knoll, G 2018, 'Establishing a Core Outcome Measure for Graft Health: A Standardized Outcomes in Nephrology-Kidney Transplantation (SONG-Tx) Consensus Workshop Report', *Transplantation*, vol. 102, no. 8, pp. 1358-1366. <https://doi.org/10.1097/TP.0000000000002125>

**Digital Object Identifier (DOI):**

[10.1097/TP.0000000000002125](https://doi.org/10.1097/TP.0000000000002125)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Transplantation

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



## Establishing a Core Outcome Measure for Graft Health: a Standardized Outcomes in Nephrology – Kidney Transplantation (SONG-Tx) Consensus Workshop Report

**Authors:** Allison Tong PhD<sup>1,2</sup>, Benedicte Sautenet<sup>3</sup>, Emilio D. Poggio<sup>4</sup>, Krista L. Lentine<sup>5</sup>, Rainer Oberbauer<sup>6</sup>, Roslyn Mannon<sup>7</sup>, Barbara Murphy<sup>8</sup>, Benita Padilla<sup>9</sup>, Kai Ming Chow<sup>10</sup>, Lorna Marson<sup>11</sup>, Steve Chadban<sup>12</sup>, Jonathan C. Craig<sup>1,2</sup>, Angela Ju<sup>1,2</sup>, Karine E. Manera<sup>1,2</sup>, Camilla S. Hanson<sup>1,2</sup>, Michelle A. Josephson<sup>13</sup>, Greg Knoll<sup>14</sup> on behalf of the SONG-Tx Graft Health Workshop Investigators\*

\*A complete list of the SONG-Tx Graft Loss Workshop investigators is provided in Supplementary File 1.

### **Affiliations:**

<sup>1</sup>Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia

<sup>2</sup>Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia

<sup>3</sup>Department of Nephrology and Clinical Immunology, University Francois Rabelais, Tours Hospital, Tours, France; INSERM, U1246, Tours, France

<sup>4</sup>Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, United States

<sup>5</sup>Saint Louis University Center for Abdominal Transplantation, MO, United States

<sup>6</sup>Department of Internal Medicine, University of Vienna, Austria, Vienna

<sup>7</sup>School of Medicine, University of Alabama Birmingham, AL, United States

<sup>8</sup>Department of Medicine, Mount Sinai Hospital, New York, NY, United States

<sup>9</sup>Department of Adult Nephrology, National Kidney and Transplant Institute, Philippines

<sup>10</sup>Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong

<sup>11</sup>Transplant Unit, University of Edinburgh, Edinburgh, United Kingdom

<sup>12</sup>Department of Renal Medicine, Royal Prince Alfred Hospital, Central Clinical School, The  
University of Sydney, Sydney, Australia

<sup>13</sup>Department of Medicine, The University of Chicago, Chicago, IL, United States

<sup>14</sup>Division of Nephrology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada

**Address for correspondence:**

Allison Tong

Centre for Kidney Research. The Children's Hospital at Westmead, Westmead, NSW 2145

Sydney, Australia

Phone: +61 2 9845 1467 Fax: +61 2 9845 1491 Email: [allison.tong@sydney.edu.au](mailto:allison.tong@sydney.edu.au)

**Authors' specific contributions:**

1 AT participated in the research design, data collection, data analysis, and drafted the manuscript.

2  
3 BS participated in the research design, data collection, data analysis, and drafted the manuscript.

4  
5 EP participated in the research design, data collection, data analysis, and provided intellectual input  
6  
7 on the manuscript and contributed to manuscript writing.

8  
9  
10 KLL participated in the research design, data collection, data analysis, and provided intellectual  
11  
12 input on the manuscript and contributed to manuscript writing.

13  
14  
15 RO participated in the research design, data collection, data analysis, and provided intellectual input  
16  
17 on the manuscript and contributed to manuscript writing.

18  
19  
20 RBM participated in the research design, data analysis, and provided intellectual input on the  
21  
22 manuscript and contributed to manuscript writing.

23  
24  
25 BM participated in the research design, data analysis, and provided intellectual input on the  
26  
27 manuscript and contributed to manuscript writing.

28  
29  
30 BP participated in the research design, data analysis, and provided intellectual input on the  
31  
32 manuscript and contributed to manuscript writing.

33  
34  
35 KMC participated in the research design, data analysis, and provided intellectual input on the  
36  
37 manuscript and contributed to manuscript writing.

38  
39  
40 LM participated in the research design, data analysis, and provided intellectual input on the  
41  
42 manuscript and contributed to manuscript writing.

43  
44  
45 SC participated in the research design, data analysis, and provided intellectual input on the  
46  
47 manuscript and contributed to manuscript writing.

48  
49  
50 JCC participated in the research design, data analysis, and provided intellectual input on the  
51  
52 manuscript and contributed to manuscript writing.

53  
54  
55 AJ participated in the research design, data collection, data analysis, and provided intellectual input  
56  
57 on the manuscript and contributed to manuscript writing.

58  
59  
60 KM participated in the research design, data collection, data analysis, and provided intellectual  
61  
62 input on the manuscript and contributed to manuscript writing.

CSH participated in the research design, data collection, data analysis, and provided intellectual input on the manuscript and contributed to manuscript writing.

MAJ participated in the research design, data collection, data analysis, and provided intellectual input on the manuscript and contributed to manuscript writing.

GK participated in the research design, data collection, data analysis, and provided intellectual input on the manuscript and contributed to manuscript writing.

**Disclosure:** The authors declare no conflicts of interest.

**Funding:** This project is supported by a National Health and Medical Research Council Project Grant 1128564 and Program Grant 1092957. AT is supported by a NHMRC Career Development Fellowship 1106716.

**Abbreviations:**

Standardized Outcomes in Nephrology (SONG)

## Abstract

1  
2  
3 **Background:** Graft loss, a critically important outcome for transplant recipients, is variably defined  
4  
5 and measured, and incompletely reported in trials. We convened a consensus workshop on  
6  
7 establishing a core outcome measure for graft loss for all trials in kidney transplantation.  
8  
9

10  
11  
12 **Methods:** Twenty-five kidney transplant recipients/caregivers and 33 health professionals from  
13  
14 eight countries participated. Transcripts were analyzed thematically.  
15  
16  
17

18  
19  
20 **Results:** Five themes were identified. “*Graft loss as a continuum*” conceptualizes graft loss as a  
21  
22 process, but requiring an endpoint defined as a discrete event. In “*defining an event with precision*  
23  
24 *and accuracy*,” loss of graft function requiring chronic dialysis (minimum 90 days) provided an  
25  
26 objective and practical definition; re-transplant would capture pre-emptive transplantation; relisting  
27  
28 was readily measured but would overestimate graft loss; and allograft nephrectomy was redundant  
29  
30 in being preceded by dialysis. However, the thresholds for renal replacement therapy varied.  
31  
32 Conservative management was regarded as too ambiguous and complex to use routinely.  
33  
34 “*Distinguishing death-censored graft loss*” would ensure clarity and meaningfulness in interpreting  
35  
36 results. “*Consistent reporting for decision-making*” by specifying time points and metrics (i.e. time  
37  
38 to event) was suggested. “*Ease of ascertainment and data collection*” of the outcome from  
39  
40 registries could support use of registry data to efficiently extend follow-up of trial participants.  
41  
42  
43  
44  
45  
46  
47  
48

49 **Conclusions:** A practical and meaningful core outcome measure for graft loss may be defined as  
50  
51 chronic dialysis or re-transplant, and distinguished from loss due to death. Consistent reporting of  
52  
53 graft loss using standardized metrics and time points may improve the contribution of trials to  
54  
55 decision-making in kidney transplantation.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Introduction

1  
2  
3 Advances in kidney transplantation have yielded remarkable improvements in short-term graft  
4 survival. In most high-income countries, more than 95% of recipients have a functioning graft at  
5 one year post-transplant<sup>1-3</sup>. However, the rates of graft survival decline to 50-70% after 10 years<sup>4-6</sup>,  
6 and 20-30% after 20 years<sup>7,8</sup>. Limited improvements in long-term outcomes have been achieved and  
7 there have been calls to reform trial design in transplantation<sup>9</sup>. Losing a graft is a critical outcome  
8 for patients with a kidney transplant and their clinicians. Many recipients regard this as the most  
9 important outcome, even above mortality, as they fear the return to dialysis<sup>10,11</sup>. Yet, many trials  
10 conducted in kidney transplantation do not report graft loss at a time point that is meaningful to  
11 patients<sup>12-17</sup>. Moreover, graft loss is variably defined, measured and sometimes not even reported in  
12 trials<sup>18</sup>.

13  
14  
15 Systematic reviews of trials in kidney transplant recipients consistently show that graft loss is  
16 reported using different definitions (return to chronic dialysis, allograft nephrectomy, re-transplant),  
17 metrics (such as proportion or time to event), and do not consistently report death-censored graft  
18 loss<sup>17,19,20</sup>. Collectively, these problems limit the value of trials in supporting decision-making,  
19 make cross trial comparisons problematic, and ultimately impede progress in achieving better long-  
20 term graft outcomes.

21  
22  
23 Recently, the Standardized Outcomes in Nephrology – Kidney Transplantation (SONG-Tx)  
24 initiative established six consensus-based core outcomes of critical importance to all stakeholders:  
25 graft health, mortality, cardiovascular disease, infection, cancer, and life participation<sup>11,21,22</sup>. Core  
26 outcomes are intended to ensure consistent reporting of data from clinical trials and do not  
27 necessarily have to be selected as the primary outcome for the trial. Graft health was composed of  
28 four graft-related outcome domains: graft loss, acute graft rejection, chronic graft rejection and graft  
29 function<sup>22</sup>; with graft loss identified by all stakeholders as the most important to report in trials<sup>11,22</sup>.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

The emphasis of this workshop is on establishing a consensus-based definition for graft loss and not all graft-related outcomes. This workshop report aims to describe the perspectives of patients, caregivers, and health professionals on establishing a core outcome measure for graft loss, including the definition and metric, to be used in all trials conducted in kidney transplant recipients.

## Context and scope

The SONG-Tx Graft Health consensus workshop was convened in Chicago May 1<sup>st</sup> 2017 during the American Transplant Congress. Consensus workshop is one step in establishing core outcome measure<sup>23</sup>, by bringing together the insights from experts to enable decisions to be made.

Participants were asked to discuss and provide specific input on establishing a core outcome measure for graft loss – including the definition and metric to measure graft loss in all trials in kidney transplantation. Graft loss was identified as a core outcome to be reported in all trials in kidney transplantation based on consensus among patients, caregivers, and health professionals.

Ensuring that trials report critically important outcomes (i.e. graft loss) in a consistent way enables reliable assessment of the comparative effect of interventions across trials, and ultimately improves the relevance, reliability, and efficiency of trials to support treatment decision-making<sup>21,22</sup>. The core outcome does not preclude individual trialists from using additional outcomes measures that are of specific relevance to the trial. Core outcome sets are a set of outcomes that should be reported as a minimum in clinical trials for a specific clinical area, however they do not necessarily have to be used as the primary endpoint of the trial.

To prompt the discussion, we presented a preliminary definition for graft loss based on definitions that have been used in trials in kidney transplantation: “need for kidney replacement therapy (chronic dialysis for more than 90 days, repeat kidney transplant, conservative management)”; and examples of metrics (time to event, proportion with a functioning graft at a given time point). We



clarified that graft loss would be addressed separate from mortality (i.e. death with a functioning graft).

## **Attendees and contributors**

Fifty-eight stakeholders attended the workshop; 16 (28%) were patients with a kidney transplant, 9 (15%) were caregivers, and 33 (57%) were health professionals including nephrologists, surgeons, psychiatrists, psychologists, nurses, researchers, policy makers, and industry representatives. The attendees were from eight countries including Australia, Austria, Canada, France, Norway, United Kingdom, United States, and Vietnam. We identified “key informant” health professionals with clinical experience in kidney transplantation, and/or with interest and expertise in research focussed on graft outcomes. We also invited health professionals with an advisory or leadership role in relevant professional societies (including the American Society of Transplantation (AST), The Transplantation Society (TTS), Canadian Society of Transplantation (CST), Transplantation Society of Australia and New Zealand (TSANZ)), regulatory and agencies (including the Food and Drug Administration (FDA), United Network for Organ Sharing (UNOS)), funding organizations (National Institutes of Health (NIH)), and registries (including the Scientific Registry of Transplant Recipients (SRTR), UK Renal Registry, Australian and New Zealand Dialysis and Transplantation Registry (ANZDATA)). Patients and caregivers who resided in the United States were invited by local SONG-Tx Graft Health workshop investigators, and received reimbursement for parking and ground transportation. All contributors who were unable to attend the workshop received a copy of the workshop program, materials and draft report to provide feedback and comment (Supplemental File 1).

## **Workshop program and break out discussions**

1 All contributors and attendees received the workshop program and background materials two weeks  
2 prior to the workshop. To maximize diverse discussion and broad knowledge exchange among  
3 different stakeholders, all participants were pre-assigned to one of six break out discussion groups  
4 comprising a mix of patients/caregivers and health professionals. After a short presentation on the  
5 SONG-Tx initiative and current measures for graft health, the breakout discussions commenced.  
6  
7 Each group had a facilitator who prompted the discussion using a question guide developed in  
8 planning calls with the SONG-Tx Graft Health Expert Working Group (Supplemental File 2).  
9  
10 Participants were asked to provide feedback and suggestions regarding the definition of graft loss to  
11 be measured in clinical trials (including definition, and metric), and other considerations in  
12 selecting or developing the core outcome measure for graft loss. The groups reconvened to provide  
13 a brief summary in the final plenary session, which was moderated by the workshop Chair (G.K.).  
14  
15 At the conclusion of the workshop, the Chair (G.K.) summarized the key points presented across all  
16 groups.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 The plenary and break out discussions were audio-taped and transcribed verbatim. All transcripts  
33 were imported into HyperRESEARCH software for qualitative data management. First author  
34 (A.T.) read and coded the transcripts line by line to identify themes related to establishing a core  
35 outcome measures for graft health. A draft workshop report containing a description of the themes  
36 was sent to all participants and contributors (including those who did not attend) who were invited  
37 to provide feedback. Comments provided within a two-week time frame were integrated into the  
38 final report.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 51 **SYNTHESIS OF WORKSHOP DISCUSSION**

52  
53  
54  
55

56 We identified five themes that reflected the diversity and perspectives on establishing a core  
57 outcome measure for graft loss: graft loss as a continuum; defining an event with precision and  
58 accuracy (loss of graft function requiring chronic dialysis was accepted as a practical definition,  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

distilling the relevance of re-transplant, re-listing, and allograft nephrectomy, variability in thresholds for renal replacement therapy, ambiguity of conservative management); distinguishing death-censored graft loss; consistent reporting for decision-making; and ease of ascertainment and data collection. Selected quotations for each theme are provided in Table 1. Table 2 presents a summary of the recommendations that arose from the consensus workshop.

### **Graft loss as a continuum**

Graft loss was conceptualized by health professionals as a “continuum” whereby “the graft may be failing but the patient does not need to be on dialysis.” Some defined this as “graft health, because graft loss is not usually something that is immediate, it is sometimes a projection.” The trajectory from chronic kidney disease (CKD) to graft loss was not perceptibly different – “where does CKD and failing, before you are on dialysis, where does that come in?” However, participants agreed that in the context of trials, graft loss needed to be defined as a discrete event for pragmatic reasons including standardization.

### **Defining an event with precision and accuracy**

#### ***Chronic dialysis as a practical definition***

Health professionals agreed that graft loss could be defined as requiring chronic dialysis for more than 90 days as this was a “straightforward,” “clear,” and “precisely defined” measure, a discrete event for which the date could be easily recorded. Although the time frame of 90 days was recognized as “arbitrary,” chronic dialysis could be used to distinguish “acute or short-lived [graft failure] versus the longer chronic ones,” and served as a reasonable “database” or “regulatory” definition. However, health professionals acknowledged the “gaps in the definition”. The chances of recovering graft function during this time frame was possible, although such occurrences were

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

noted to be rare. Some remarked that the risk of mortality was high during this three-month period, and were uncertain about classifying this as graft failure or death. They also identified the need to ensure that the “data lock date” did not prevent a trial participant who recommenced dialysis thirty days prior to data lock from being recorded as graft loss. For example, a trial investigator may be certain that the graft has been lost on clinical grounds and started the patient on chronic dialysis, yet the clinical research associate (or trial monitor) may insist that this cannot be recorded as a true “graft loss” as the patient had not been on dialysis for 90 days. Thus, it was suggested that the definition could be expanded to include “dialysis commenced for the long-term in the estimation of the caring clinician.” From the patients’ perspective, dialysis signified graft loss – “as a patient, I look at going on dialysis as a failure, period, a real switch point in your minds saying, ‘ok I guess the graft has failed’.”

### ***Distilling the relevance of re-transplant, re-listing, and allograft nephrectomy***

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Re-transplant was also considered a clear and clinically important event that was important to include in the definition as patients could be pre-emptively re-transplanted without return to chronic dialysis. In particular, this would be relevant in countries where a living donor kidney transplant could be performed prior to listing, including in countries without robust deceased donor kidney transplant systems. However, one clinician argued, “I would favor re-listing as opposed to re-transplantation because sadly, there will be many patients that reach a point of re-listing and they may well die waiting and those should be considered graft losses not death with a functioning graft, even if they are eking [to endure] it out with the barest minimum of kidney function.”

Re-listing a patient on the transplant waiting list could be considered as graft loss, and was recognized by health professionals as a “key decision” that could be readily recorded. For some patients, being re-listed signified graft loss:

1 “If your doctor came up and said your kidney’s down to less than 20%, I’m going to put you  
2 on the transplant list, now you’re not on dialysis, would you feel that your transplant is  
3 failing?” (clinician)  
4

5  
6  
7 “... Yes, as a matter of fact it happened. Before my numbers got low enough, I was  
8 confronted with another cadaveric kidney transplant.” (patient)  
9

10  
11  
12 In contrast, some health professionals reasoned that re-listing “did not make sense and was more  
13 arbitrary than starting dialysis” and could occur when the GFR was 20 ml/min/1.73m<sup>2</sup> and patients  
14 could still live reasonably well for many years. Many kidney transplant recipients could be placed  
15 on the waiting list for several months without requiring dialysis. Therefore, using re-listing as a  
16 measure may overestimate graft loss. Some patients/caregivers also commented that re-listing  
17 wasn’t “necessarily a failure” because patients were being re-listed with “higher GFRs”.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 Some health professionals argued that transplant nephrectomy was a clearly defined event that  
33 could be included in the definition of graft loss; however others stated that this could be confusing  
34 as “only a small proportion of patients who lose their graft have a transplant nephrectomy.” Also,  
35 allograft nephrectomy would be “associated with the need for renal replacement therapy” and was  
36 therefore “redundant.”  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 ***Variability in thresholds for renal replacement therapy*** 47

48  
49  
50  
51 The variability in thresholds for intervention with replacement therapy was identified by clinicians  
52 as a challenge to defining graft loss consistently. Timing of chronic dialysis initiation was described  
53 as a “moving target” that changed over time – “we used to start people on dialysis closer to [a GFR]  
54 of 20 [ml/min/1.73m<sup>2</sup>], but now it’s getting into the single digits.” Some clinicians reflected that  
55  
56  
57  
58  
59  
60  
61 “we’re very bad at managing chronic graft dysfunction and failure, so we’re very late to prepare for  
62  
63  
64  
65

1  
2  
3 dialysis.” However, other clinicians observed that some patients were being re-listed earlier “when  
4 they may be at [a GFR of] 15 or 20, when they haven’t lost a graft at that point”; and in some  
5 countries (such as Norway, which has pre-emptive repeat transplant policies), patients with  
6 declining GFRs were monitored closely to be re-listed with higher GFRs of 20 ml/min/1.73m<sup>2</sup>. In  
7 contrast, clinicians raised concerns about the disparities in re-listing and re-transplant among  
8 patients from ethnic minority groups or different socio-economic status who had “different reasons  
9 for why transplants fail, people not taking their medications, they’re not going to get re-listed so  
10 you are waiting for them to go to zero, but for some you wait to go to 20...”

### 11 12 13 14 15 16 17 18 19 20 *Ambiguity of conservative management*

21  
22  
23  
24 While health professionals recognized that some patients may choose to forgo renal replacement  
25 therapy should their graft fail, adding conservative management in the definition of graft loss was  
26 regarded as too imprecise, ambiguous, and complex as it was difficult to determine an exact metric  
27 or date. Some suggested that including conservative management would allow for a more  
28 comprehensive definition of graft loss, and could be recorded as the date of the patients’ decision to  
29 decline dialysis or re-transplant. However, many contended that conservative management was  
30 “quandary from a physician perspective” as patients could change their mind about treatment, and  
31 that the decision could be made whilst the patient still had a functioning graft and thus would  
32 “create a huge bias by misclassifying [graft loss].” Some patients suggested that conservative  
33 management could be included to “educate and empower patients” by making patients aware of the  
34 option. Whilst clinicians agreed that conservative management should be included in  
35 communication with patients, they explained that conservative management was difficult to  
36 measure in the context of a clinical trial.

37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

To account for patients with graft loss who did not commence dialysis or were not re-listed/re-transplanted but died due to graft failure, it was suggested that death due to end-stage kidney

disease may be considered in defining graft loss (i.e. based on GFR). However, health professionals identified problems with this definition. For example, patients “may have low levels of GFR and may subsequently be admitted to hospital with pneumonia, chronic heart failure, or something else, deteriorate and may die, then death may be attributed to “pneumonia” or “sepsis” rather than end-stage kidney disease. Also, they reasoned that theoretically, the graft still “functions” until the time of death, irrespective of the cause of death. Separating all-cause mortality from graft loss, and defining graft loss as the need for chronic dialysis and repeat kidney transplant would be “very objective, reproducible, and easy to track in registries.”

### **Distinguishing death-censored graft loss**

There was consensus among health professionals to report “death as a separate outcome” and “differentiate graft loss due to death.” Some remarked that registries, for example in the United States, currently recorded death as graft loss. The UK registry used three definitions: graft survival (censored for death), patient survival, and transplant survival (where death is not censored). Also, trials typically reported death with a functioning graft to be graft loss. Death-censored graft loss was regarded as a meaningful outcome that should be presented explicitly in a trial. Death-censored graft loss was “interpreted as a new loss of the kidney, the kidney lost to rejection or some other causes; a different way of assessing newer drugs for example, as opposed to death. Both are meaningful. If you can save kidneys with the drugs but you lose the patient, that’s not very good.” Patients confirmed that, “For graft failure, I think less of death, I think of the kidney failing.”

### **Consistent reporting for decision-making**

Participants emphasized the need for consistent reporting of graft loss to support decision-making. One patient remarked, “in all these trials, you have recorded it one way, and you reported it in a different way, it’s hard for a doctor to talk to a patient because everybody is saying something

1 different, if you would make it more universal, then it would be easy for us to make an informed  
2 decision.” Health professionals specifically recommended that “dates were critical” and suggested  
3 to pre-specify time points – “capture it [graft loss] at least on an annual basis beyond one year.”  
4  
5 Some suggested that it would be easy to assess the proportion of patients with graft loss at specific  
6  
7 time points (e.g. at five years), and also that “time to event was a pretty standard way of analyzing  
8  
9 it, and more flexible than a defined point of time.” Time to event could be readily interpreted, and  
10  
11 would also decrease the tendency to have trials that were short in duration. Moreover, health  
12  
13 professionals advocated that trials needed to “build into the study longer follow up, to get more  
14  
15 people to contribute to the information for that assessment.”  
16  
17  
18  
19  
20  
21

## 22 **Ease of data collection and ascertainment**

23  
24  
25  
26

27 Another key consideration identified by health professionals was ease in collecting the data  
28  
29 including ascertainment in terms of “data source, or patient-reported, provider report, registry  
30  
31 report,” of which all would require “hard outcomes.” The existing capture of dialysis initiation, re-  
32  
33 listing and re-transplant in many national registries provides an opportunity to use registry data for  
34  
35 longer-term follow-up of trial participants through data integration with minimal additional cost or  
36  
37 complexity. To facilitate data linkage with registries, this may require discussion with national  
38  
39 authorities who regulate what data are collected for the ESKD population and processes for data  
40  
41 access.  
42  
43  
44  
45  
46  
47  
48

## 49 **DISCUSSION**

50  
51  
52  
53

54 In the context of a clinical trial, graft loss needs to be defined as a precise and discrete event.  
55  
56 Chronic dialysis (for more than 90 days) provides a practical and meaningful definition for graft  
57  
58 loss. From the perspective of health professionals, this definition is clinically meaningful and easily  
59  
60 recorded as an event; from the perspective of patients, dialysis signifies failure of the graft. Re-  
61  
62  
63  
64  
65



1 transplant is required in the definition as patients could be pre-emptively transplanted. The other  
2 definitions considered including re-listing, allograft nephrectomy, conservative management, and  
3 death due to end-stage kidney disease, are more ambiguous and contentious. Health professionals  
4 acknowledge that some inconsistency in defining graft loss is inevitable because of the global  
5 variability in thresholds for dialysis initiation or re-listing. Re-listing could occur when a patient  
6 had a GFR as high as 20 ml/min/1.73m<sup>2</sup>, and thus would overestimate graft loss and it would not be  
7 precise enough as an event to be used in the context of a trial. Death due to graft loss (or end-stage  
8 kidney disease) was suggested; however it was too difficult to make this measure objective and  
9 reproducible. Patients, caregivers and health professionals emphasize the need for trials to report  
10 death-censored graft loss, in addition to but distinctly different from death, so they could interpret  
11 the results in a more meaningful way. Patients reiterated that they did not perceive death as graft  
12 loss.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 Other initiatives to standardize the definition of graft loss exist. The global Clinical Data  
30 Interchange Standards Consortium (CDISC) classifies graft loss as loss of a previously functioning  
31 graft or loss due to primary non-function (of which both may require dialysis, re-transplantation, or  
32 surgical removal of graft), and graft loss due to death<sup>24</sup>. They state that “dialysis is often presumed  
33 to be irreversible after 90 days.”<sup>24</sup> Of note, relisting for kidney transplantation was not explicitly  
34 included in the definition. As identified during our workshop, this may be because patients can be  
35 re-listed with sufficient graft function without significant physical or mental impairment; and thus  
36 cannot be used to define graft loss. The European Medicines Agency 2008 Guideline on Clinical  
37 Investigation of Immunosuppressants for Solid Organ Transplantation advises the use of clear-cut  
38 and discrete criteria for graft loss “such as permanent return to pre-transplantation treatment  
39 modality for a defined period of time e.g., return to dialysis for at least 4–6 weeks or more, renal re-  
40 transplantation, nephrectomy in kidney transplantation.”<sup>25</sup> The U.S. FDA recommends that “the  
41 diagnosis of primary nonfunction generally does not become established before 2 to 3 months (90  
42 days) after transplantation<sup>26</sup>. As previously noted, the SONG-Tx core outcomes are established to  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

ensure that there is consistent reported of data across clinical trials in transplantation and do not have to be used as the primary outcome to determine sample size of the trial.

There is broad consensus among all stakeholders that graft loss is a critically important outcome to be reported in trials<sup>11,22</sup>. However, trials in kidney transplantation are typically short in duration<sup>12-14</sup> and therefore unlikely to demonstrate a difference in the effect of an intervention on graft loss.

There are now increasing calls for trials to conduct longer-follow up. The existing capture of dialysis initiation, re-transplant, and re-listing in many national registries provides an opportunity for data integration strategies to extend the follow-up of trial participants with minimal added cost or complexity<sup>27</sup>. As emphasized by the workshop participants and contributors, the ease of data collection and ascertainment are necessary to support implementation of a core outcome measure for graft loss – including in registries.

The recommendations for establishing a core outcome measure for graft loss shown in Table 2 are based on the collective input from patients, caregivers, and health professionals. We acknowledge that the majority of participants were from high-income, English-speaking countries and patients were recruited from Chicago because of feasibility. However, we elicited input from participants in low-income countries and the discussion and the recommendations that arose from the workshop appear to be internationally applicable and relevant. This workshop focussed on developing a core outcome measure for graft loss.

More broadly, we acknowledge other efforts to define endpoints related to graft health. The U.S. FDA has developed guidance on surrogate endpoints in kidney transplantation including delayed graft function<sup>26</sup>, and in the past year convened workshops to address surrogate endpoints for clinical trials in kidney transplantation<sup>28</sup>, and antibody-mediated rejection<sup>29</sup>. Another example is the ongoing work by the Banff initiative since 1991 in developing the classification of renal allograft biopsies, which integrates histologic, serologic, and molecular diagnostic techniques to produce a

consensus-based reporting system for graft rejection<sup>30-32</sup>. However, there is no accepted or FDA-approved surrogate endpoint for graft loss<sup>9</sup>.

The workshop recommendations will directly inform the proposal of a core outcome measure for graft loss that will be piloted prior to broader implementation in trials, and with the growing interest in registry-based trials, potentially also in registries. Further detailed and technical work on the measurement and analysis of graft loss will be undertaken. Establishing and implementing a core outcome measure for graft loss in all trials in kidney transplant is likely to improve consistency in trial reporting, and thereby strengthen the evidence-base for shared decision-making to improve the care and outcomes of kidney transplant recipients.

## Acknowledgements

1  
2  
3 We acknowledge, with permission, all the attendees listed below who attended the consensus  
4  
5 workshop.  
6

7  
8  
9  
10 *Health professionals (\*includes two patients from the SONG-Tx Graft Health Expert Working*  
11  
12 *Group)* – Zeeshan Butt, Kevin Fowler, Camilla Hanson, Paul Harden, Carmel Hawley, Hallvard

13 Holdaas, Ajay Israni, Michelle Jesse, Michelle Josephson, Sheila Jowsey-Gregoire, Angela Ju,

14  
15 Brenna Kane, John Kanellis, Bryce Kiberd, Joseph Kim, Greg Knoll, Chris Larsen, Alan

16  
17  
18  
19  
20 Leichtman, Krista Lentine, Andrew Malone, Karine Manera, Roslyn Mannon, Rainer Oberbauer,

21  
22 Rachel Patzer, John Devin Peipert, Hai An Phan, Emilio Poggio, Rihannon Reed, Benedicte

23  
24  
25 Sautenet, John Scandling, Jane Tan, Ignatius Tang, Quinetta Taylor, Allison Tong, Chris Watson,  
26

27  
28  
29  
30 *Patients and family members* – Daniel Contrares, Patricia Contreras, Daley Cross, Egle Juodvalkis,

31  
32 Den Koide, Jinny Koide, Adam Kozarewicz, Laura Kozarewicz, Richard Kozarewicz, Andrea

33  
34  
35 Koritala, Elizabeth Lisiecki, Christine Lipuma, Margaret Lyman, Robert Mueller, Gloria Mueller,

36  
37 Larry Noble, Nancy Nolan, Stephen Nolan, Jim Thomas, Lynda Urbanczyk, James Zerante, Susan

38  
39 Zerante  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med.* 2007;357(25):2562-2575.
2. GODT. Global Observatory on Donation and Transplantation - Organ donation and transplantation activities 2014 available at <http://www.transplant-observatory.org/data-reports-2014/> (Accessed 14th December 2016). 2014.
3. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. *Am J Transplant.* 2011;11(3):450-462.
4. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. *Lancet.* 2011;378(9800):1428-1437.
5. Ojo AO, Morales JM, González-Molina M, et al. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. *Nephrol Dial Transplant.* 2013;28(1):213-220.
6. Pippias M, Stel VS, Aresté-Fosalba N, et al. Long-term kidney transplant outcomes in primary glomerulonephritis: analysis from the ERA-EDTA registry. *Transplant.* 2016;100(9):1955-1962.
7. Traynor C, Jenkinson A, Williams Y, et al. Twenty-year survivors of kidney transplantation. *Am J Transplant.* 2012;12(12):3289-3295.
8. McCaughan JA, Courtney AE. The clinical course of kidney transplant recipients after 20 years of graft function. *Am J Transplant.* 2015;15:734-740.
9. O'Connell PJ, Kuypers DR, Mannon RB, et al. Clinical trials for immunosuppression in transplantation: the case for reform and change in direction. *Transplant.* 2017;101(7):1527-1534.
10. Howell M, Tong A, Wong G, Craig JC, Howard K. Important outcomes for kidney transplant recipients: a nominal group and qualitative study. *Am J Kidney Dis.* 2012;60(2):186-196.
11. Sautenet B TA, Manera KE, Chapman JR, Warrens AN, Rosenbloom D, Wong G, Gill J, Budde K, Rostaing L, Marson L, Josephson MA, Reese PP, Pruett TL, Hanson CS,

O'Donoghue D, Tam-Tham H, Halimi JM, Shen JI, Kanellis J, Scandling JD, Howard K, Howell M, Cross N, Evangelidis N, Masson P, Oberbauer R, Fung S, Jesudason S, Knight S, Mandayam S, McDonald S, Chadban S, Rajan T, Craig JC. . Developing consensus-based priority outcome domains for trials in kidney transplantation: a multinational Delphi survey with patients, caregivers and health professionals. *Transplant*. 2017;101(8):1875-1886.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

12. Molnar AO, Fergusson D, Tsampalieros AK, et al. Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. *Br Med J*. 2015;350:h3163.
13. Howell M, Wong G, Rose J, Tong A, Craig JC, Howard K. The consistency and reporting of quality of life outcomes in trials of immunosuppressive agents in kidney transplantation: a systematic review and meta-analysis. *Am J Kidney Dis*. 2016;57(6):762-774.
14. Howell M, Yeo R, Tong A, Craig JC, Howard K, Wong G. Completeness of reporting adverse events of maintenance immunosuppression in kidney transplantation: a systematic review. *Nephrol Dial Transplant*. 2017(Online first 11 July 2017).
15. Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. *Cochrane Database Syst Rev*. 2014;24(11):CD010699.
16. Hiremath S, Fergusson DA, Fergusson N, Bennett A, Knoll GA3. Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials. *Am J Kidney Dis*. 2017;69(1):78-86.
17. Haller MC, Royuela A, Nagler EV, Pascual J, Webster AC. Steroid avoidance or withdrawal for kidney transplant recipients. *Cochrane Database Syst Rev*. 2016;8:CD005632.
18. Masson P, Duthie FA, Ruster LP, et al. Consistency and completeness of reported outcomes in randomized trials of primary immunosuppression in kidney transplantation. *Am J Transplant*. 2013;13(11):2892-2901.
19. Wagner M, Earley AK, Webster AC, Schmid CH, Balk EM, Uhlig K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. *Cochrane Database Syst Rev*. 2015;12:CD007746.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
20. Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. *Cochrane Database Syst Rev.* 2017;1(CD004759).
  21. Tong A, Budde K, Gill J, et al. Standardized outcomes in nephrology - transplantation: a global initiative to develop a core outcome set for trials in kidney transplantation. *Transplant Direct.* 2016;2(6):e79.
  22. Tong A, Gill J, Budde K, et al. Toward establishing core outcome domains for trials in kidney transplantation: report of the standardized outcomes in nephrology - kidney transplantation consensus workshops. *Transplant.* 2017;10(8):1887-1896.
  23. Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. *Trials.* 2017;18:280.
  24. CDISC. *Therapeutic area data standards user guide for kidney transplant Version 1.0 (provisional)*. Austin, TX: Clinical Data Interchange Standards Consortium;2016.
  25. EMA. Guideline on the Clinical Investigation of Immunosuppressants for Solid Organ Transplantation Doc. Ref. CHMP/EWP/263148/06 (Available at [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2009/09/WC500003593.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003593.pdf), Accessed 13th September 2017). London: European Medicines Agency; 2008.
  26. FDA. *Delayed graft function in kidney transplantation: developing drugs for prevention. Guidance for industry.* . Rockville MD, United States: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); March 2017 2017.
  27. Lentine KL, Schnitzler MA, Xiao H, Brennan DC. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants. *Trials.* 2015;16:635.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

28. FDA. FDA Workshop: Surrogate endpoints in clinical trials of kidney transplantation (available at <https://www.fda.gov/downloads/Drugs/NewsEvents/UCM459437.pdf>, accessed 13th September 2017). U.S. Food and Drug Administration; 2015.
29. FDA. Antibody mediated rejection in kidney transplantation available at <https://www.fda.gov/Drugs/NewsEvents/ucm532070.htm> (Accessed November 27th, 2017). U.S. Food and Drug Administration: Silver Spring, MD 20993; 2017.
30. Loupy A, Haas M, Solez K, et al. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. *Am J Transplant.* 2017;17(1):28-41.
31. Gimeno J, Redondo D, Pérez-Sáez MJ, Naranjo-Hans D, Pascual J, Crespo M. Impact of the Banff 2013 classification on the diagnosis of suspicious versus conclusive late antibody-mediated rejection in allografts without acute dysfunction. *Nephrol Dial Transplant.* 2016;31(11):1938-1946.
32. Solez K. History of the Banff classification of allograft pathology as it approaches its 20th year. *Curr Opin Organ Transplant.* 2010;15(1):49-51.



**Table 1. Quotations to support each theme**

<b>Themes and illustrative quotations</b>	
1	<b>Graft loss as a continuum</b>
2	
3	From the physician standpoint, in a way it's a continuum, the graft maybe failing but they don't need to be on dialysis,
4	sometimes we can just keep the transplant going for a long time. So graft loss, is basically, it stops working, and you go back
5	on dialysis. H5
6	When I have a lot of patients with failing grafts, before they get on dialysis, they're sometimes really miserable, on phosphate
7	binders and doing well and they're tired.... where does CKD, where does CKD and failing, before you are on dialysis, where
8	does that come in? H5
9	When I think of graft loss, I think of graft health, because graft loss is usually not something that is immediate, it's sometimes a
10	projection just as we all age, things will slowly get better or worse. H6
11	<b>Defining an event with precision and accuracy</b>
12	<b>Chronic dialysis as a practical definition</b>
13	
14	The 90 days in the US, after 12 weeks of lets, say acute renal failure and being on dialysis, chances of recovering kidney
15	function sufficient enough to be off dialysis are low so that's why, we fill out the form, end-stage kidney disease, we wait that
16	time, in fact this is also the highest period when the patients are at high risk for dying so, first three months, who survives the
17	three months. H4
18	From the patient perspective, needing dialysis is a negative thing...from the scientific perspective, it's either being on dialysis,
19	and or reaching the point of needing a kidney. H4
20	It's clear cut, if you have dialysis for 3 months, that's reasonable, the only problem with the three months thing is that some
21	people will have as you mention irrecoverable renal function and die at 6 weeks, so what is that, is that graft failure or is that
22	death? H4
23	We have to make a distinction here between the acute loss versus chronic one, in an acute one, 30 days, the kidney come
24	back, in the chronic one the GFR of 20 but the kidney function goes down slowly, on dialysis because you lost your kidney
25	function gradually or, so patients who are sick and they get on dialysis, most of them come back, so that's why you have to
26	wait for three months. H4
27	I could see when you have insertion of the peritoneal dialysis catheter or the creation of vascular access, I can see how that
28	would be a real switch point in your minds saying ok I guess its failed, and it's your dialysis, cause we just did something. H4
29	This is the definition we do in a lot of drug studies that we do...getting on dialysis for 90 days is a regulatory definition and
30	sometimes is used as an endpoint so when you're trying a new drug, measuring whether the drug is better than Drug A, versus
31	what you are on now. If you end up on dialysis and it's called a graft loss, then that drug probably won't get approved so it's a
32	tough definition. H5
33	I feel sad for the patient who has to go back on dialysis. P6
34	An issue on the chronic dialysis piece, that 90 day rule is a pretty arbitrary one. Patients could have an illness that causes their
35	kidney to not function well for only a temporary period, and so that they could get dialysis in the meantime, but most times it
36	doesn't last longer than 90 days, they get better and they come off dialysis, that wouldn't really be a graft loss per se, so that
37	90 day window is trying to sort of tease out the ones that are quote unquote acute or shortlived versus the longer chronic ones,
38	the problem there is that you have to wait until that happens to decide, at the time you don't know which way this person's
39	going to go and once you decide where time zero is, is it the 90 day point or is it the origin at which you do dialysis, from a
40	survival analysis perspective. The bottom line is I think that has to be clarified. But the kidney replacement therapy piece is
41	quite reasonable. H6
42	Sometimes its just very difficult to distinguish and say for someone with heart problems whose kidneys fail they went on
43	dialysis and they were able to come off but it doesn't mean they were able to achieve the same level of function as they did
44	before because the heart was so sick, the heart disease, it may have had a role to play in changing the level of kidney function
45	as you now resume with afterwards so it has its own impact so to speak. So that's where I think, reading this, if we're talking
46	about graft loss, that is one area I'm wondering how we are going to address, it has come up in trials. H6
47	<b>Distilling relevance of re-transplant, re-listing, and allograft nephrectomy</b>
48	
49	On the list of things that are included in the graft loss definition, nephrectomy is not there, which seems like an oversight,
50	nephrectomy is clear. H2
51	One thing was that whether allograft nephrectomy should be included but that would really be associated with the need for
52	renal replacement therapy so I suppose that would be redundant. H3
53	I don't think that transplant nephrectomy should be included, categorised in trials, because only a small proportion of patients
54	who lose their graft have a transplant nephrectomy so its confusing. H4
55	Before my numbers got low enough I was confronted with another cadaveric kidney transplant so I was one of the people that
56	never actually went back on dialysis, thank god cause it's a horrible life, the diet, the restrictions, its nasty, and so that's failure,
57	just like you were saying, that's failure, so that's graft loss. P4
58	Re-listing is not necessarily a failure, my wife an example of that, she never went through dialysis, and couldn't go through
59	dialysis so just the fact that she relisted wouldn't necessarily be a failure, and it was pointed out that more and more people are
60	going on the wait list with higher GFRs like in that 15 to 20 range so that sort of is a major factor considered in that may not
61	have existed years ago. (Plenary)
62	<b>Variability of thresholds for renal replacement therapy</b>
63	
64	It is a bit of a moving target though I mean we used to start people on dialysis closer to [a GFR of] 20 but now it's like getting
65	

into the single digits. H1

I was just thinking what the definition was, the start of dialysis which is basically the very same one, if you want to have a non-precise definition, if you're a patient treated in the profit unit, the provider might suggest you have a GFR of 15, that's not sufficient and you start dialysis. H2

Things are changing. We're very bad at managing chronic graft dysfunction and failure, so we're very late to prepare for dialysis, now that's changing and now we are looking at people with GFRs under 20, native renal disease patients, and in some places they've got separate clinics for the failing graft. I don't think its graft loss at that point, it's a bit like advanced chronic kidney disease. The kidneys haven't totally failed, but we are getting better at preparing people for re-transplantation. We're re-transplanting people earlier when they maybe [a GFR of] 15 or 20, they haven't lost their graft at that point, it could be 6 to 12, 18 months because we are intervening earlier, so how do you allow for that, when we are making that conservative decision earlier as well so that we are better at giving EPO. H4

This has moved a bit, I don't think we treat these people quite optimally we should be treating these people like the, pre-dialysis clinics that we have or the low clearance clinics, so how do you allow for that? If you categorize everybody. H4

My only concern is that different ethnic groups and different socio-economic status, have different reasons why transplants fail, people not taking their medications, they're not going to get re-listed so you are waiting for them to go to zero, but you wait for some to go to 20. H4

#### **Ambiguity of conservative management**

Conservative management part, I'm not sure how you measure that, so someone could say I don't want it now but then when they get sick they might change their mind, it is a bit of a quandary from a physician perspective. H1

Conservative management is a choice, but when it would occur? It's hard, if you're having the discussion, the doctor might say 'I think you need to start dialysis now' and you're saying 'well I don't really want to ever start dialysis.' That's hard to define that as a starting point because you may live weeks to months. H1

It's pretty imprecise, our ability to prognosticate, it's pretty off. H1

That's my only problem with taking it out of there of the definition. The definitions are there to educate and empower patients by telling them all of that, if a patient, they are able to self-educate themselves about what their options are. P1

A more technical issue with conservative management thing is that a lot of trials are moving to save money. Now they're trying to link up to all these other databases that exist in the United States, but there's one in Canada, Australia, European countries, so there would be no measurement of conservative care in these kind of databases. It would add an issue of potentially cost and complexity, it does add to the practicality of it, I would just see people not implementing it. H1

If you are getting to that point and having that conversation, the patient chooses not to pursue it that's one thing but really the discrete starting point seems to be the conversation, the identification of failure kidneys and discussion of treatment options and even it its not perfect because it'll be hard to track. H2

There's a huge north south gradient, at least in Europe, there's England or the Nordic countries, they had a lot of patients, in Italy, there's nobody that's ever withdrawn from dialysis. H2

Because if you are thinking about a new therapy, the whole idea of having these endpoints is that we have better clinical trial design, and if the endpoint is your function is so poor, you need renal replacement therapy, you want to be comprehensive to include the conservative management, to me that's a treatment failure. H5

Conservative management is quite non-descript in terms of how you want to capture that in trials, it would be open to interpretation of what that is, and also it's really intent not to pursue dialysis, so that would have to be defined, to make sure that's been applied appropriately. (Plenary)

#### **Distinguishing death censored graft loss**

The flip side is if you don't include that then everybody that, the doctor says you either need to start dialysis or re-transplant we don't have something like that and patients say I don't want to do those two, that would never be counted as graft loss, and then your numbers are off, because they will eventually pass away but they won't be counted as graft loss even though their kidney function was really really bad, you have to include them somehow. H1 ...But they would be counted as a death in a trial. H1 ...But the graft loss is a separate definition and that would be undercounted. H1

It was a very clear rationale for having death as a separate outcome, for instance the SRTR, which is our national registry, you guys count death as a graft loss. H1 ... So nephrologists might say oh that's not fair, there's a car accident, that didn't have anything to do with my kidney care. I've actually had conversations with people, they said well that graft is no longer functioning, that's the definition we're talking about and so I'm curious from this standpoint, I know they are making a very different, they're trying hard to separate that but that's going to conflict with some major other reports. H1

I think less of death, I think of kidney failing. P2

The traditional way of reporting graft loss is death with a functioning graft but then some people also report death censored graft loss, they both have meaning, but in my view is that they, they both ought to be presented, or if you present, death-censored, you have to be clear that it is death censored. H3

Suppose the aim is have death with functioning graft, but to have a prolonged life and not a premature death, so the aim is to keep it working, there's sort of nuances to the data. H3

Graft loss for a clinician is very difficult, it's very depressing for the individual, but we need to differentiate between graft loss due to death which I don't think is graft loss because the graft is often still functioning and in many trials, it's very confusing, and that's something which I think should be clarified. Death should be death, and graft loss shouldn't be included in that. H4

Sadly there will be many patients that reach a point of re-listing and they may well die waiting and those should be considered graft losses not death with a functioning graft even if they are eking it out with the barest minimum of kidney function, that's where I think re-listing captures a very meaningful outcome that failures of the graft. H4

The other thing is death with a functioning graft, because that of course is a graft loss. When we record stats in the UK, we

	record transplant survival meaning graft loss with death. H5 You will see the Kaplan-Meier, will have death censored graft loss, and the metric for one year, patient death. H5
1	<b>Consistent reporting for decision-making</b>
2	So one would say 6 months after the transplant, the other would say 8% functioning at one year. H3
3	You also have to talk about the kidney totally failing, and then it has to be universal, like you said all these trials, but you have
4	recorded it one way, you reported it in a different way, it's hard for a doctor to talk to a patient because everybody is saying
5	something different, so if you would make it more universal then it would be easy for us to make an informed decision. P4
6	The way the data are analysed sometimes isn't lined up with what the intent of the investigator is so there is a bit of a
7	disconnect. In this case I agree dates are critical, do we have to pre-specify, do we have to come to consensus around what
8	time points we report. H6
9	Grafts can last very long, that's the goal, then you really would have to capture it at least on an annual basis beyond the year.
10	H6
11	What's at stake here is when you only have five people die in one group and two people die in the other group, in a year, does
12	that provide any meaningful information about for example new treatments affecting people? Probably not. So as a result you
13	would have to build into the study longer follow up, to get more people to contribute to the information for that assessment or
14	more patients, to provide you more data. The other thing to inform this is the biology. So the reasons why kidneys are lost
15	within the first year versus beyond the first year are different. If you are interested in those causes that cause kidney loss in the
16	first year, then naturally you want to study losses in the first year, you can't just study five or two patients, so you need more
17	patients followed over a year. Alternatively, in things that occur after a year then you may be able to follow the hundred
18	patients for longer but then you have to make sure that you achieve the follow up, so it depends on what you are looking at
19	ultimately, H6
20	<b>Ease of data collection and ascertainment</b>
21	That would be my worry, they would say 'I know this has been recommended but we're not doing it because we're going to
22	save way more money by this'. H1
23	Which one is easier to measure, that's what they're looking for. H1
24	Did that mean ascertainment in terms of data source, or patient reported, provider report, registry report, cause all these
25	different sources have varying levels of, but at the heart of it these, they're good, they're hard outcomes. H3
26	One of the considerations is the ease in gathering the data, so if everything went into a central registry...the ease with which
27	you can find the data is important, H3
28	The easiest one to measure, to capture, is the kidney transplant, the hardest one to measure is the conservative management
29	and somewhere in between chronic dialysis depending on how you are going to capture that. H5
30	Time to event is pretty standard way of analysing it, it's more flexible then a defined point in time. H5

H, health professional, P, patient, C, caregiver/family member, number indicated refers to Group ID (1 – 6)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 2. Summary of workshop recommendations for establishing a core outcome measure for graft loss**

<b>Implications for establishing a core outcome measure for graft loss</b>
<ul style="list-style-type: none"><li>• The core outcome measure for graft loss requires a precise definition.</li><li>• Chronic dialysis for more than 90 days should be included in the definition for graft loss as this is precisely defined, clear, and is the current definition used in registries and by regulatory agencies.</li><li>• Repeat kidney transplant should be included in the definition for graft loss because some patients may be pre-emptively re-transplanted without return to chronic dialysis.</li><li>• Re-listing for kidney transplantation can be readily measured, however patients may be re-listed with relatively good kidney function and thus may overestimate graft loss, and it would not be a precise enough event to be used in the context of a trial.</li><li>• It may not be informative to include allograft nephrectomy in the definition for graft loss as this is a rare event and is associated with the need for renal replacement therapy (i.e. chronic dialysis or transplant).</li><li>• It would not be feasible to include conservative management in the definition for graft loss because of ambiguity, complexity and inconsistency in the definition, and it would be difficult to determine an exact time of event.</li><li>• Death due to end-stage kidney disease would not provide an objective and reproducible measure therefore cannot be included in the definition of graft loss.</li><li>• Death (from any cause) should be reported as a separate outcome to graft loss.</li><li>• Death-censored graft loss should be reported as this is meaningful to all stakeholders.</li><li>• A standard metric should be established i.e. time to event or a consistent time point for measurement (i.e. at least annually) to enable informed decision-making.</li></ul>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



Click here to access/download

**Supplemental Digital Content to Be Published (cited in text)**

Supplemental Digital Content TPA2017-1409R1.docx





Click here to access/download

**Main - Clean Copy (To Include:Title page, Text,  
Abstract, References, and Tables.)**

**TPA2017-1409R2-vCleanCopy-20180118.docx**